Secarna, Vect-Horus partner to develop RNA-targeted therapeutics
Secarna Pharmaceuticals and Vect-Horus have entered a research collaboration for developing RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) for treating central nervous system (CNS) diseases.